(June 29, 2018) Avastin, or bevacizumab, was recently approved by the FDA to be used first with chemotherapy, then by itself, after surgery… Read on
(May 18, 2018) Just last month, three of OCRFA’s research advocates attended the 5 day AACR meeting in Chicago, Illinois to learn about new therapies and innovative technology, stay up to date on current projects, and attend lectures from… Read on
(May 4, 2018) JAMA Oncology recently published a study that looked at the risk of breast cancer in BRCA1 carriers who underwent a prophylactic bilateral salpingo-oophorectomy, a surgery that removes both ovaries before any sign of disease, followed… Read on
(April 27, 2018) An OCRFA supported study, recently published in Oncogene, delved into the mechanics of how ovarian cancer spreads throughout the body… Read on
(April 26, 2018) The International Journal of Gynecological Cancer recently featured a retrospective study on the treatment patterns of women with advanced high-grade serous ovarian carcinoma (HGSC)… Read on
(April 24, 2018) Science Advances recently published a study that succeeded in detecting HE4, a biomarker for high-grade serous ovarian cancer (HGSC), by implanting an optical sensor near a disease site in mice… Read on
(April 17, 2018) Science Translational Medicine recently published a University of Pennsylvania Perelman School of Medicine/University of Lausanne, Switzerland study on using a patient’s immune system to fight their cancer… Read on
(April 10, 2018) Patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who have had at least a partial response to platinum based chemotherapy have a new, FDA approved option for maintenance therapy… Read on
(April 4, 2018) It’s an exciting time for ovarian cancer research! Ovarian cancer clinicians, researchers and advocates came together in New Orleans at the end of March for the Annual Meeting on Women’s Cancer, hosted by the Society of… Read on
(April 3, 2018) A study in the Journal of Clinical Oncology explored the effects of oncologists, rather than genetic counselors, testing ovarian cancer patients for BRCA mutations… Read on
